Dr. Sachs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Fruit St
Yawkey 8b
Boston, MA 02114Phone+1 617-726-2737Fax+1 617-724-0702
Education & Training
- Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 2004 - 2007
- Tufts Medical CenterResidency, Pediatrics, 2001 - 2004
- Washington University in St. Louis School of MedicineClass of 2001
Certifications & Licensure
- MA State Medical License 2007 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2016 Aug 01
- Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma Start of enrollment: 2017 Oct 04
- Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2018 Feb 22
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsResults from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20B Cell Lymphoma.Javier Munoz, Ian W Flinn, Jonathon B Cohen, Jessica Sachs, Benjamin Exter
Transplantation and Cellular Therapy. 2024-02-01 - 397 citationsBrentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s LymphomaJoseph M. Connors, Wojciech Jurczak, David J. Straus, Stephen M. Ansell, Won Kim
The New England Journal of Medicine. 2017-12-10 - 12 citationsNonalloreactive T Cells Prevent Donor Lymphocyte Infusion–Induced Graft-versus-Host Disease by Controlling Microbial StimuliHao Wei Li, Jessica Sachs, Clarimel Pichardo, Roderick T. Bronson, Guiling Zhao
Journal of Immunology. 2012-12-15
Abstracts/Posters
- Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ non-Hodgkin LymphomaJessica Sachs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell LymphomaJessica Sachs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
- Unum Therapeutics Inc. Announces Acquisition of Kiq LLCJuly 6th, 2020
- Unum Therapeutics Strengthens and Expands Leadership TeamJune 13th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: